Clinical Immunogenicity Risk Assessment for a Fusion Protein.
Saved in:
| Title: | Clinical Immunogenicity Risk Assessment for a Fusion Protein. |
|---|---|
| Authors: | Sperinde G; BioAnalytical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA. gizette@gene.com., Montgomery D; Predictive and Clinical Immunogenicity, Merck & Co., Inc., West Point, PA, USA., Mytych DT; Clinical Immunology-Translational Medicine, Amgen Inc., Thousand Oaks, CA, USA. |
| Source: | The AAPS journal [AAPS J] 2020 Apr 03; Vol. 22 (3), pp. 64. Date of Electronic Publication: 2020 Apr 03. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: American Association of Pharmaceutical Scientists Country of Publication: United States NLM ID: 101223209 Publication Model: Electronic Cited Medium: Internet ISSN: 1550-7416 (Electronic) Linking ISSN: 15507416 NLM ISO Abbreviation: AAPS J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
